AFT Pharmaceuticals Limited (AFT) Earnings Call Transcripts

AFT Pharmaceuticals Limited's Latest Earnings Call - May 20, 2026

AFT Pharmaceuticals reported strong FY '26 results, achieving revenue of $254.7 million, up 22% year-over-year, and an operating profit of $24.4 million, slightly exceeding guidance. The company reaffirmed its revenue target of $300 million for FY '27, supported by ongoing expansion in key markets and a robust R&D pipeline. Management indicated a profit forecast of $28 million to $32 million for the upcoming fiscal year, reflecting confidence in continued growth despite challenges in some international markets.

Reported metrics

Guidance from management

Management reaffirmed a revenue target of at least $300 million for FY '27 and a profit forecast of $28 million to $32 million, indicating confidence in growth despite market uncertainties.

What management said

Yes. We see -- over time, we do see we can get further improvements out of it. I guess the one provider is like if we see a really good opportunity there, we would take it. So if we see something going particularly strong as a new launch, we would put more money behind it. But yes, we see we can get more leverage going forward in -- particularly in Australia.

Yes. So overall, it is -- the underlying products still continue to grow. The -- for Australasia, there's around about a total of about $6 million that came out of products we've launched of that $6 million growth from the products we've launched in the last 3 years.

What analysts pressed on

Analysts expressed concerns regarding the profitability of the international segment, particularly in the U.S. and Canada. There were questions about the timeline for achieving breakeven in these markets and the impact of increased operational costs on margins.

Main topics on the call

• Revenue Growth — AFT Pharmaceuticals achieved revenue of $254.7 million, representing a 22% increase year-over-year. CEO Hartley Atkinson stated, "We managed to get to $254.7 million, up 22%, which is about a 17.6% 5-year CAGR."
• Operating Profit Performance — The operating profit was reported at $24.4 million, slightly ahead of guidance. This reflects a significant increase from $17.6 million in the previous year, indicating effective cost management despite increased investm...
• International Expansion — AFT is actively expanding its global footprint, with sales initiated in 87 countries. The company is particularly focused on growth in Europe, North America, and South Africa, aiming to leverage new product launches and ...
• R&D Pipeline Development — The company highlighted a robust R&D pipeline with ongoing projects and new product launches. Atkinson noted, "We are wanting to make sure we realize the value and monetize the R&D pipeline," indicating a strategic focus...

Read the full AFT Pharmaceuticals Limited transcript (May 20, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 17 AFT Pharmaceuticals Limited earnings call transcripts on record, spanning May 19, 2020 to July 30, 2026. Based on this history, AFT Pharmaceuticals Limited reports semi-annually. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

AFT

Exchange

NZSE

Country

NZ

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

17

First call

May 19, 2020

Most recent

July 30, 2026

Reporting cadence

semi-annually